By Exec Edge Editorial Staff
IQVIA (NYSE: IQV) and clinical-stage biopharmaceutical company Medera Inc. announced a strategic collaboration aimed at accelerating the development of cardiac gene therapies and human-based drug discovery platforms.
Under the partnership, Medera’s Sardocor unit will use IQVIA’s clinical trial, regulatory and commercialization capabilities to advance FDA-cleared, first-in-human gene therapy programs targeting difficult-to-treat cardiovascular diseases. IQVIA will support patient recruitment, regulatory filings and applications for expedited FDA designations.
READ MORE
a.k.a. Brands 2Q Gross Margin Improves as Fashion Turnaround Gains Momentum
“By combining IQVIA’s global expertise with Medera’s mini-Heart platform and gene therapy programs, we can bring safer, more effective therapies to patients faster,” Medera Co-Founder, Chairman and CEO Ronald Li said. The collaboration will also support Medera’s Novoheart platform, which uses engineered human cardiac tissue for disease modeling, drug screening and toxicity testing.
Never Miss our Weekly Highlights
HERE
